Cancer immunotherapy including the use of immune checkpoint inhibitors (ICI) and chimeric antigen receptor T cell therapy (CAR-T) are showing a promising role as part of cancer therapy and slowly replacing conventional chemotherapy. However, the use of ICI and CAR-T in organ transplant recipients with malignancies could be complicated with acute rejection and graft loss. Many proposed immunosuppressive (IS) regimens showed a probable role in preventing acute rejection related to ICI, including the use of a single ICI rather than double ICI, concomitant use of glucocorticoids (GC), converting tacrolimus to mTor inhibitors (m-TorI) and avoid close sequencing of ICI agents. Furthermore, low dose prednisone (LDP) before CAR-T infusion in patients with stable allograft kidney function could favor the regulatory T cells (T-regs), actively regulating alloimmune responses, and maintaining self-tolerance of the renal transplant. Further prospective trials will be needed to examine the long-term effect of these regimens in renal transplant recipients undergoing CAR-T or receiving ICI as curative therapies for their refractory cancers.
RosnerMHPerazellaMA.Acute kidney injury in patients with cancer. N Engl J Med2017; 376(18): 1770–1781.
2.
HodiFSO’DaySJMcDermottDF, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med2010; 363(8): 711–723.
3.
BrahmerJReckampKLBaasP, et al. Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer. N Engl J Med2015; 373(2): 123–135.
4.
PorterDLLevineBLKalosM, et al. Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. N Engl J Med2011; 365(8): 725–733.
5.
GruppSAKalosMBarrettD, et al. Chimeric antigen receptor-modified T cells for acute lymphoid leukemia. N Engl J Med2013; 368(16): 1509–1518.
6.
WanchooRKaramSUppalNN, et al. Adverse renal effects of immune checkpoint inhibitors: a narrative review. Am J Nephrol2017; 45(2): 160–169.
7.
SuryKPerazellaMA.The nephrotoxicity of new immunotherapies. Expert Rev Clin Pharmacol2019; 12(6): 513–521.
8.
PerazellaMAShiraliAC.Nephrotoxicity of cancer immunotherapies: past, present and future. J Am Soc Nephrol2018; 29(8): 2039–2052.
9.
ZhangEXuH.A new insight in chimeric antigen receptor-engineered T cells for cancer immunotherapy. J Hematol Oncol2017; 10(1): 1.
10.
SiuJHYSurendrakumarVRichardsJA, et al. T cell allorecognition pathways in solid organ transplantation. Front Immunol2018; 9: 2548.
11.
NajafianNKhourySJSayeghMH.T cell costimulatory blockade as a novel immune intervention in autoimmune diseases. Clin Dermatol2001; 19(5): 586–591.
12.
GracaLCobboldSPWaldmannH.Identification of regulatory T cells in tolerated allografts. J Exp Med2002; 195(12): 1641–1646.
13.
ZhengXXSánchez-FueyoAShoM, et al. Favorably tipping the balance between cytopathic and regulatory T cells to create transplantation tolerance. Immunity2003; 19(4): 503–514.
14.
D’AddioFYuanXHabichtA, et al. A novel clinically relevant approach to tip the balance toward regulation in stringent transplant model. Transplantation2010; 90(3): 260–269.
15.
RiellaLVPatersonAMSharpeAH, et al. Role of the PD-1 pathway in the immune response. Am J Transplant2012; 12(10): 2575–2587.
16.
VaddepallyRKharelPPandeyR, et al. Review indications of FDA-approved immune checkpoint inhibitors per NCCN guidelines with the level of evidence. Cancers2020; 12(3):738.
17.
AlhamadTVenkatachalamKLinetteGP, et al. Checkpoint inhibitors in kidney transplant recipients and the potential risk of rejection. Am J Transplant2016; 16(4): 1332–1333.
18.
LipsonEJBagnascoSMMooreJJr, et al. Tumor regression and allograft rejection after administration of anti-PD-1. N Engl J Med2016; 374(9): 896–898.
19.
SpainLHigginsRGopalakrishnanK, et al. Acute renal allograft rejection after immune checkpoint inhibitor therapy for metastatic melanoma. Ann Oncol2016; 27(6): 1135–1137.
20.
BoilsCLAljadirDNCantafioAW.Use of the PD-1 pathway inhibitor nivolumab in a renal transplant patient with malignancy. Am J Transplant2016; 16(8): 2496–2497.
21.
KeanLSTurkaLABlazarBR, et al. Advances in targeting co-inhibitory and co-stimulatory pathways in transplantation settings: the Yin to the Yang of cancer immunotherapy. Immunol Rev2017; 276(1): 192–212.
22.
LipsonEJBodellMAKrausES, et al. Successful administration of ipilimumab to two kidney transplantation patients with metastatic melanoma. J Clin Oncol2014; 32(19): e69–71.
23.
RanganathHAPanellaTJ.Administration of ipilimumab to a liver transplant recipient with unresectable metastatic melanoma. J Immunother2015; 38(5): 211.
24.
MoralesREShoushtariANWalshMM, et al. Safety and efficacy of ipilimumab to treat advanced melanoma in the setting of liver transplantation. J Immunotherapy Cancer2015; 3: 22.
25.
StarkeALindenmeyerMSegererS, et al. Renal tubular PD-L1 (CD274) suppresses alloreactive human T-cell responses. Kidney Int2010; 78(1): 38–47.
26.
MillerDMFaulkner-JonesBEStoneJR, et al. Complete pathologic response of metastatic cutaneous squamous cell carcinoma and allograft rejection after treatment with combination immune checkpoint blockade. JAAD Case Rep2017; 3(5): 412–415.
27.
WeberJSD’AngeloSPMinorD, et al. Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomized, controlled, open-label, phase 3 trial. Lancet Oncol2015; 16(4): 375–384.
28.
PowellJDDelgoffeGM.The mammalian target of rapamycin: linking T cell differentiation, function, and metabolism. Immunity2010; 33(3): 301–311.
29.
VanasekTLKhorutsAZellT, et al. Antagonistic roles for CTLA-4 and the mammalian target of rapamycin in the regulation of clonal anergy: enhanced cell cycle progression promotes recall antigen responsiveness. J Immunol167(10): 2001; 5636–5644.
30.
LonghiMSMaYBogdanosDP, et al. Impairment of CD4(+)CD25(+) regulatory T-cells in autoimmune liver disease. J Hepatol2004; 41(1): 31–37.
31.
BaxevanisCNPapamichailM.Targeting of tumor cells by lymphocytes engineered to express chimeric receptor genes. Cancer Immunol Immunother2004; 53(10): 893–903.
32.
KochenderferJNWilsonWHJanikJE, et al. Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19. Blood2010; 116(20): 4099–4102.
33.
BrentjensRJDavilaMLRivieraI, et al. CD19-targeted T cells rapidly induce molecular remissions in adults with chemotherapy-refractory acute lymphoblastic leukemia. Sci Transl Med2013; 5(177): 177ra138.
34.
CruzCRYMicklethwaiteKPSavoldoB, et al. Infusion of donor-derived CD19-redirected virus-specific T cells for B-cell malignancies relapsed after allogeneic stem cell transplant: a phase 1 study. Blood2013; 122(17): 2965–2973.
35.
KochenderferJNDudleyMECarpenterRO, et al. Donor-derived CD19-targeted T cells cause regression of malignancy persisting after allogeneic hematopoietic stem cell transplantation. Blood2013; 122(25): 4129–4139.
36.
MaudeSLFreyNShawPA, et al. Chimeric antigen receptor T cells for sustained remissions in leukemia. N Engl J Med2014; 371(16): 1507–1517.
37.
DavilaMLRiviereIWangX, et al. Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia. Sci Transl Med2014; 6(224): 224–225.
38.
KochenderferJNDudleyMEKassimSH, et al. Chemotherapy-refractory diffuse large B-cell lymphoma and indolent B-cell malignancies can be effectively treated with autologous T cells expressing an anti-CD19 chimeric antigen receptor. J Clin Oncol2015; 33(6): 540–549.
39.
LeeDWKochenderferJNStetler-StevensonM, et al. T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial. Lancet2015; 385(9967): 517–528.
40.
GarfallALMausMVHwangW-T, et al. Chimeric antigen receptor t cells against cd19 for multiple myeloma. N Engl J Med2015; 373(11): 1040–1047.
41.
FraiettaJABeckwithKAPatelPR, et al. Ibrutinib enhances chimeric antigen receptor T-cell engraftment and efficacy in leukemia. Blood2016; 127(9): 1117–1127.
42.
BrudnoJNKochenderferJN.Toxicities of chimeric antigen receptor T cells: recognition and management. Blood2016; 127(26): 3321–3330.
43.
KebriaeiPSinghHHulsMH, et al. Phase I trials using sleeping beauty to generate CD19-specific CAR T cells. J Clin Invest2016; 126(9): 3363–3376.
44.
TurtleCJHanafiLABergerC, et al. CD19 CAR-T cells of defined CD4+:CD8+ composition in adult B cell ALL patients. J Clin Invest2016; 126(6): 2123–2138.
45.
TurtleCJHanafiLABergerC, et al. Immunotherapy of non-Hodgkin’s lymphoma with a defined ratio of CD8+ and CD4+ CD19-specific chimeric antigen receptor-modified T cells. Sci Transl Med2016; 8(355): 355ra116.
46.
KochenderferJNSomervilleRPTLuT, et al. Lymphoma remissions caused by anti-cd19 chimeric antigen receptor t cells are associated with high serum interleukin-15 levels. J Clin Oncol2017; 35(16): 1803–1813.
LockeFLGhobadiAJacobsonCA, et al. Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1-2 trial. Lancet Oncol2019; 20(1): 31–42.
50.
NeelapuSSLockeFBartlettNL, et al. Kte-C19 (anti-CD19 CAR T cells) induces complete remissions in patients with refractory diffuse large B-cell lymphoma (DLBCL): results from the pivotal phase 2 zuma-1. Blood2016; 128(22): LBA-6.
51.
GillSMausMVPorterDL, et al. Chimeric antigen receptor T cell therapy: 25years in the making. Blood Rev2016; 30(3): 157–167.
52.
OlnesMJKotliarovYBiancottoA, et al. Effects of systemically administered hydrocortisone on the human immunome. Sci Rep2016; 6: 23002.
53.
HaynesBFFauciAS.The differential effect of in vivo hydrocortisone on the kinetics of subpopulations of human peripheral blood thymus-derived lymphocytes. J Clin Invest1978; 61(3): 703–707.
54.
MathianAJouenneRChaderD, et al. Regulatory T cell responses to high-dose methylprednisolone in active systemic lupus erythematosus. PLoS One2015; 10(12): e0143689.
55.
HuangHLuZJiangC, et al. Imbalance between Th17 and regulatory T-cells in sarcoidosis. Int J Mol Sci2013; 14(11): 21463–21473.
56.
LanzaLScudelettiMPuppoF, et al. Prednisone increases apoptosis in in vitro activated human peripheral blood T lymphocytes. Clin Exp Immunol1996; 103(3): 482–490.
57.
BrahmerRLacchettiCSchneiderBJ, et al. Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy. J Clin Oncol2018; 36(17): 1714–1768.
58.
HorvatTZAdelNGDangTO, et al. Immune-related adverse events, need for systemic immunosuppression, and effects on survival and time to treatment failure in patients with melanoma treated with ipilimumab at memorial sloan kettering cancer center. J Clin Oncol2015; 33(28): 3193–3198.
59.
MaudeSLBarrettDTeacheyDT, et al. Managing cytokine release syndrome associated with novel T cell-engaging therapies. Cancer J2014; 20(2): 119–122.
60.
IshiiKShalabiHYatesB, et al. Tocilizumab-refractory cytokine release syndrome (CRS) triggered by chimeric antigen receptor (car)-transduced T cells may have distinct cytokine profiles compared to typical CRS. Blood2016; 128(22): 3358.
